Number 5: Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Aislinn Antrim serves as Managing Editor at Pharmacy Times.

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from 2022, what's to come in 2023, and how the US biosimilars market is expected ...

The Increasing Access to Biosimilars Act of 2023 (HR 1352), a bill that would direct HHS to establish a demonstration project within Medicare that would establish a shared savings model for ...